Although the introduction of bortezomib as a therapeutic strategy has improved the overall survival of multiple myeloma (MM) patients, 15-20% of high-risk patients do not respond to bortezomib over time or become resistant to treatment. Therefore, the development of new therapeutic strategies, such as combination therapies, is urgently needed.
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma / Di Lernia, Giuseppe; Leone, Patrizia; Solimando, Antonio Giovanni; Buonavoglia, Alessio; Saltarella, Ilaria; Ria, Roberto; Ditonno, Paolo; Silvestris, Nicola; Crudele, Lucilla; Vacca, Angelo; Racanelli, Vito. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:2(2020), pp. 55201-55214. [10.3390/jcm9020552]
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
Racanelli, Vito
2020-01-01
Abstract
Although the introduction of bortezomib as a therapeutic strategy has improved the overall survival of multiple myeloma (MM) patients, 15-20% of high-risk patients do not respond to bortezomib over time or become resistant to treatment. Therefore, the development of new therapeutic strategies, such as combination therapies, is urgently needed.| File | Dimensione | Formato | |
|---|---|---|---|
|
2020 JCM Autophagy.pdf
accesso aperto
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Creative commons
Dimensione
3.91 MB
Formato
Adobe PDF
|
3.91 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
